cilostazol Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	644	73963-72-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: OPC 13013 cilostazol cilostazole pletal OPC-13013	A quinoline and tetrazole derivative that acts as a phosphodiesterase type 3 inhibitor, with anti-platelet and vasodilating activity. It is used in the treatment of PERIPHERAL VASCULAR DISEASES; ISCHEMIC HEART DISEASE; and in the prevention of stroke. Molecular weight: 369.47 Formula: C20H27N5O2 CLOGP: 3.53 LIPINSKI: 0 HAC: 7 HDO: 1 TPSA: 81.93 ALOGS: -4.06 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

OPC 13013
cilostazol
cilostazole
pletal
OPC-13013

A quinoline and tetrazole derivative that acts as a phosphodiesterase type 3 inhibitor, with anti-platelet and vasodilating activity. It is used in the treatment of PERIPHERAL VASCULAR DISEASES; ISCHEMIC HEART DISEASE; and in the prevention of stroke.

Molecular weight: 369.47
Formula: C20H27N5O2
CLOGP: 3.53
LIPINSKI: 0
HAC: 7
HDO: 1
TPSA: 81.93
ALOGS: -4.06
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.20	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.00 mg/mL	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	7.73 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
Jan. 15, 1999	FDA	OTSUKA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cerebral infarction	94.31	15.39	49	5537	23317	46657159
Ventricular fibrillation	40.40	15.39	22	5564	11474	46669002
Cardiac failure	35.93	15.39	46	5540	79902	46600574
Acinetobacter test positive	32.09	15.39	6	5580	82	46680394
Nikolsky's sign	30.48	15.39	6	5580	109	46680367
Cerebral haemorrhage	28.35	15.39	25	5561	28346	46652130
Anaemia	26.73	15.39	79	5507	255700	46424776
Urticaria vesiculosa	26.58	15.39	4	5582	12	46680464
Aortic dissection	25.90	15.39	9	5577	1583	46678893
Pyogenic granuloma	24.71	15.39	6	5580	296	46680180
Drug ineffective	24.67	15.39	27	5559	677811	46002665
Cardiac failure congestive	24.08	15.39	41	5545	91709	46588767
Beta-N-acetyl-D-glucosaminidase increased	22.73	15.39	4	5582	38	46680438
Interstitial lung disease	22.60	15.39	30	5556	53919	46626557
Ventricular tachycardia	21.18	15.39	17	5569	16950	46663526
Hepatic function abnormal	20.71	15.39	23	5563	34398	46646078
Haemorrhage subcutaneous	20.64	15.39	9	5577	2897	46677579
Gastrointestinal haemorrhage	19.54	15.39	34	5552	77339	46603137
Torsade de pointes	19.17	15.39	14	5572	12140	46668336
Parotid gland enlargement	18.97	15.39	6	5580	788	46679688
Blood urea increased	18.92	15.39	19	5567	25333	46655143
Subarachnoid haemorrhage	17.94	15.39	13	5573	11140	46669336
Blood pressure decreased	16.95	15.39	27	5559	57132	46623344
Acute leukaemia	16.85	15.39	6	5580	1132	46679344
Kounis syndrome	16.53	15.39	6	5580	1196	46679280
Liver disorder	16.03	15.39	21	5565	37225	46643251
Melaena	15.75	15.39	18	5568	27754	46652722
Enterobacter test positive	15.71	15.39	4	5582	240	46680236
Shock	15.62	15.39	16	5570	21829	46658647
Peripheral arterial occlusive disease	15.50	15.39	8	5578	3744	46676732

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cerebral infarction	125.65	14.14	86	9108	26287	29916997
Hepatic function abnormal	68.49	14.14	74	9120	41871	29901413
Interstitial lung disease	60.39	14.14	83	9111	60114	29883170
Peripheral arterial occlusive disease	59.82	14.14	30	9164	5138	29938146
Haemorrhage subcutaneous	35.08	14.14	16	9178	2221	29941063
Altered state of consciousness	33.99	14.14	36	9158	19883	29923401
Sprue-like enteropathy	31.04	14.14	9	9185	338	29942946
Toxicity to various agents	29.31	14.14	9	9185	177174	29766110
Intermittent claudication	28.92	14.14	14	9180	2220	29941064
Thrombosis in device	25.53	14.14	15	9179	3511	29939773
Hemiplegia	25.42	14.14	19	9175	6642	29936642
Cerebral haemorrhage	25.22	14.14	40	9154	32847	29910437
Decreased appetite	24.58	14.14	101	9093	149809	29793475
Gastric ulcer haemorrhage	24.49	14.14	17	9177	5297	29937987
Lacunar infarction	24.37	14.14	14	9180	3141	29940143
Renal impairment	23.73	14.14	68	9126	84116	29859168
Haematochezia	22.71	14.14	39	9155	34183	29909101
Drug ineffective	22.63	14.14	44	9150	340343	29602941
Gastrointestinal haemorrhage	22.17	14.14	66	9128	83380	29859904
Cardiac failure	21.24	14.14	65	9129	83353	29859931
Cerebral hyperperfusion syndrome	21.13	14.14	5	9189	83	29943201
Pneumonia aspiration	19.94	14.14	39	9155	37741	29905543
Carotid artery stenosis	19.39	14.14	14	9180	4640	29938644
Thrombotic cerebral infarction	19.06	14.14	6	9188	299	29942985
Contrast encephalopathy	18.87	14.14	4	9190	39	29943245
Thalamus haemorrhage	18.73	14.14	8	9186	950	29942334
Gastric cancer	18.62	14.14	14	9180	4936	29938348
Peripheral artery occlusion	18.53	14.14	9	9185	1437	29941847
Depressed level of consciousness	18.43	14.14	38	9156	38184	29905100
Basal ganglia haematoma	17.41	14.14	4	9190	58	29943226
Acute myocardial infarction	17.13	14.14	45	9149	52894	29890390
Disseminated intravascular coagulation	17.04	14.14	27	9167	22144	29921140
Peripheral artery restenosis	16.87	14.14	3	9191	10	29943274
Fat embolism	16.71	14.14	5	9189	210	29943074
Arterial restenosis	16.16	14.14	4	9190	81	29943203
Peripheral vascular disorder	15.83	14.14	13	9181	5206	29938078
Drug eruption	15.81	14.14	23	9171	17503	29925781
Shock haemorrhagic	15.37	14.14	17	9177	9848	29933436
Hypoglycaemia	15.15	14.14	42	9152	50939	29892345
Chronic pigmented purpura	15.13	14.14	4	9190	106	29943178
Haemobilia	15.12	14.14	5	9189	292	29942992
Angioplasty	14.98	14.14	7	9187	1027	29942257
Liver disorder	14.86	14.14	30	9164	29692	29913592
Tachycardia	14.78	14.14	53	9141	73686	29869598
Transient ischaemic attack	14.51	14.14	27	9167	25173	29918111
Ventricular tachycardia	14.28	14.14	26	9168	23836	29919448
Blood pressure decreased	14.21	14.14	39	9155	47036	29896248
Venous haemorrhage	14.18	14.14	3	9191	29	29943255

Pharmacologic Action:

Source	Code	Description
ATC	B01AC23	BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Platelet aggregation inhibitors excl. heparin
FDA MoA	N0000175086	Phosphodiesterase 3 Inhibitors
FDA EPC	N0000175598	Phosphodiesterase 3 Inhibitor
MeSH PA	D018927	Anti-Asthmatic Agents
MeSH PA	D001993	Bronchodilator Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D005343	Fibrinolytic Agents
MeSH PA	D006401	Hematologic Agents
MeSH PA	D018696	Neuroprotective Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D058987	Phosphodiesterase 3 Inhibitors
MeSH PA	D010726	Phosphodiesterase Inhibitors
MeSH PA	D010975	Platelet Aggregation Inhibitors
MeSH PA	D020011	Protective Agents
MeSH PA	D019141	Respiratory System Agents
MeSH PA	D014665	Vasodilator Agents
CHEBI has role	CHEBI:35523	bronchodilator agents
CHEBI has role	CHEBI:35620	vasodilator
CHEBI has role	CHEBI:48676	fibrin modulating agents
CHEBI has role	CHEBI:50249	anticoagulante
CHEBI has role	CHEBI:50427	platelet aggregation inhibitors
CHEBI has role	CHEBI:50568	cyclic nucleotide phosphodiesterase inhibitor
CHEBI has role	CHEBI:63726	neuroprotective agents

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Intermittent claudication	indication	63491006	DOID:3669
Chronic heart failure	contraindication	48447003
Kidney disease	contraindication	90708001	DOID:557
Disease of liver	contraindication	235856003	DOID:409

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Enzyme	Q14432	PDE3A_HUMAN	INHIBITOR	IC50	6.70	IUPHAR	CHEMBL
Cytochrome P450 2C9	Enzyme	P11712	CP2C9_HUMAN		IC50	5	DRUG MATRIX
cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Enzyme	Q13370	PDE3B_HUMAN	INHIBITOR	IC50	6.42	IUPHAR

External reference:

ID	Source
4021153	VUID
N0000148605	NUI
D01896	KEGG_DRUG
4021153	VANDF
C0055729	UMLSCUI
CHEBI:31401	CHEBI
CHEMBL799	ChEMBL_ID
DB01166	DRUGBANK_ID
D000077407	MESH_DESCRIPTOR_UI
2754	PUBCHEM_CID
7148	IUPHAR_LIGAND_ID
5680	INN_ID
N7Z035406B	UNII
21107	RXNORM
14036	MMSL
60734	MMSL
7889	MMSL
d04382	MMSL
007339	NDDF
116087001	SNOMEDCT_US
395239000	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0028	TABLET	50 mg	ORAL	ANDA	27 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0044	TABLET	100 mg	ORAL	ANDA	27 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2064	TABLET	100 mg	ORAL	ANDA	28 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2065	TABLET	50 mg	ORAL	ANDA	28 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0123	TABLET	50 mg	ORAL	ANDA	29 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0223	TABLET	100 mg	ORAL	ANDA	29 sections
CILOSTAZOL	HUMAN PRESCRIPTION DRUG LABEL	1	16590-285	TABLET	100 mg	ORAL	ANDA	22 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5329	TABLET	50 mg	ORAL	ANDA	28 sections
cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	50268-176	TABLET	50 mg	ORAL	ANDA	20 sections
cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	50268-177	TABLET	100 mg	ORAL	ANDA	20 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5411	TABLET	100 mg	ORAL	ANDA	16 sections
cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	60505-2521	TABLET	50 mg	ORAL	ANDA	20 sections
cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	60505-2522	TABLET	100 mg	ORAL	ANDA	20 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	68151-3844	TABLET	50 mg	ORAL	ANDA	26 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	68151-4123	TABLET	100 mg	ORAL	ANDA	26 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	70436-050	TABLET	50 mg	ORAL	ANDA	29 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	70436-051	TABLET	100 mg	ORAL	ANDA	29 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	70436-156	TABLET	50 mg	ORAL	ANDA	28 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	70436-157	TABLET	100 mg	ORAL	ANDA	28 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	70518-2200	TABLET	100 mg	ORAL	ANDA	28 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	70518-2208	TABLET	50 mg	ORAL	ANDA	28 sections
cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	70518-2714	TABLET	100 mg	ORAL	ANDA	20 sections
Cilostazol	HUMAN PRESCRIPTION DRUG LABEL	1	71610-037	TABLET	100 mg	ORAL	ANDA	29 sections
CILOSTAZOL	HUMAN PRESCRIPTION DRUG LABEL	1	72189-116	TABLET	50 mg	ORAL	ANDA	16 sections